相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst et al.
ANNALS OF ONCOLOGY (2021)
PCN57 Cost-Effectiveness of Venetoclax in Combination with Obinutuzumab in First LINE Chronic Lymphocytic Leukemia in Colombia
J. Ordoñez et al.
VALUE IN HEALTH (2021)
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
Kishan K. Patel et al.
BLOOD (2020)
Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial
Othman Al-Sawaf et al.
LANCET ONCOLOGY (2020)
Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab Versus Chemoimmunotherapy and Other Novel Combinations in First-Line Chronic Lymphocytic Leukemia in Canada
Anuja Chatterjee et al.
BLOOD (2020)
Open science challenges, benefits and tips in early career and beyond
Christopher Allen et al.
PLOS BIOLOGY (2019)
Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions
K. Fischer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood
Seamus Kent et al.
PHARMACOECONOMICS (2019)
A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management
Natalia R. Kunst et al.
VALUE IN HEALTH (2019)
Future Costs in Cost-Effectiveness Analyses: Past, Present, Future
Linda M. de Vries et al.
PHARMACOECONOMICS (2019)
What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology?
Antonia Busse et al.
BREAST CARE (2019)
Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands
Margreet G. Franken et al.
ANTI-CANCER DRUGS (2018)
Clinical Practice Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) in The Netherlands
Sabina Kersting et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Update of the Dutch manual for costing studies in health care
Tim A. Kanters et al.
PLOS ONE (2017)
Interpretation of the Expected Value of Perfect Information and Research Recommendations: A Systematic Review and Empirical Investigation
Joanna Thorn et al.
MEDICAL DECISION MAKING (2016)
Cost Effectiveness of Ofatumumab Plus Chlorambucil in First-Line Chronic Lymphocytic Leukaemia in Canada
William Herring et al.
PHARMACOECONOMICS (2016)
Cost-effectiveness of First-line Chronic Lymphocytic Leukemia Treatments When Full-dose Fludarabine Is Unsuitable
Erkki Soini et al.
CLINICAL THERAPEUTICS (2016)
Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses Second Panel on Cost-Effectiveness in Health and Medicine
Gillian D. Sanders et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands
Hedwig M. Blommestein et al.
LEUKEMIA RESEARCH (2016)
Incidence, direct costs and duration of hospitalization of patients hospitalized with community acquired pneumonia: A nationwide retrospective claims database analysis
Mark H. Rozenbaum et al.
VACCINE (2015)
Real-world costs of chronic lymphocytic leukaemia in the Netherlands
K. M. Holtzer-Goor et al.
LEUKEMIA RESEARCH (2014)
Estimating Multiparameter Partial Expected Value of Perfect Information from a Probabilistic Sensitivity Analysis Sample: A Nonparametric Regression Approach
Mark Strong et al.
MEDICAL DECISION MAKING (2014)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia
Keith Tolley et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2013)
Improved curve fits to summary survival data: application to economic evaluation of health technologies
Martin W. Hoyle et al.
BMC MEDICAL RESEARCH METHODOLOGY (2011)
Standardizing the Inclusion of Indirect Medical Costs in Economic Evaluations
Pieter H. M. van Baal et al.
PHARMACOECONOMICS (2011)
Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study
Kathleen M. Beusterien et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2010)
Time for Cooperation in Health Economics among the Modelling Community
Renee J. G. Arnold et al.
PHARMACOECONOMICS (2010)
Assessment of transparency of cost estimates in economic evaluations of patient safety programmes
Haruhisa Fukuda et al.
JOURNAL OF EVALUATION IN CLINICAL PRACTICE (2009)
Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
Michael Drummond et al.
VALUE IN HEALTH (2009)
分享论文
